Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

ADVERTISEMENT

Chronic Lymphocytic Leukemia Excellence Forum

Chronic Lymphocytic Leukemia
Excellence Forum
Leaders in the field sharing authoritative insights and institutional best practices.

Kerry Rogers, MD
Interview
Venetoclax Plus Ibrutinib Combination Therapy for Treating Patients With CLL With Resistance Mutations
04/19/2024

Featuring Kerry Rogers, MD, The Ohio State University

Featuring Kerry Rogers, MD, The Ohio ...
Kerry Rogers, MD, The Ohio State University, discusses results from her study on how Bruton tyrosine kinase (BTK) inhibitors ibrutinib and venetoclax could help eliminate molecular resistance in patients with CLL who have resistance mutations.
Kerry Rogers, MD, The Ohio State University, discusses results from her study on how Bruton tyrosine kinase (BTK) inhibitors ibrutinib and venetoclax could help eliminate molecular resistance in patients with CLL who have resistance mutations.
Kerry Rogers, MD, The Ohio State...
04/19/2024
Journal of Clinical Pathways
John Allan, MD, Weill Cornell Medicine
Conference Coverage
Comparing BTK Inhibitors for Frontline Chronic Lymphocytic Leukemia Treatment
04/10/2024

Featuring John Allan, MD

Featuring John Allan, MD
John Allan, MD, compares the use of different BTK inhibitors for the treatment of CLL in a frontline setting and discusses whether there is an optimal drug regimen to use among patients with CLL.
John Allan, MD, compares the use of different BTK inhibitors for the treatment of CLL in a frontline setting and discusses whether there is an optimal drug regimen to use among patients with CLL.
John Allan, MD, compares the use...
04/10/2024
Lymphoma, Leukemia & Myeloma Network
Jing-Zhou Hou, MD, PhD
Videos
Clinical and Demographic Factors Impacting Treatment Selection for Patients With CLL in Community Oncology Settings
03/21/2024

Featuring Jing-Zhou Hou, MD, PhD

Featuring Jing-Zhou Hou, MD, PhD ...
Jing-Zhou Hou, MD, PhD, discusses how the standard of care for CLL has evolved among community oncologists since 2020 and how clinical and demographic factors impact treatment selection.
Jing-Zhou Hou, MD, PhD, discusses how the standard of care for CLL has evolved among community oncologists since 2020 and how clinical and demographic factors impact treatment selection.
Jing-Zhou Hou, MD, PhD,...
03/21/2024
Journal of Clinical Pathways
John Allan, MD
Conference Coverage
Novel Updates in the Chronic Lymphocytic Leukemia Treatment Landscape
03/20/2024

Featuring John Allan, MD

Featuring John Allan, MD
At the Lymphoma, Leukemia & Myeloma Congress in New York, John Allan, MD, discusses novel updates in the chronic lymphocytic leukemia treatment landscape, highlighting studies that focused on BTK inhibitor combination treatments.
At the Lymphoma, Leukemia & Myeloma Congress in New York, John Allan, MD, discusses novel updates in the chronic lymphocytic leukemia treatment landscape, highlighting studies that focused on BTK inhibitor combination treatments.
At the Lymphoma, Leukemia &...
03/20/2024
Lymphoma, Leukemia & Myeloma Network
Kerry Rogers, MD.
Videos
Recent Advancements in Chronic Lymphocytic Leukemia Care and a Look to the Future
03/07/2024

Featuring Kerry Rogers, MD

Featuring Kerry Rogers, MD
In this interview, Kerry Rogers, MD, from The Ohio State University, provides insight into the newly available treatments for chronic lymphocytic leukemia (CLL) and how care for patients with CLL has changed over time.
In this interview, Kerry Rogers, MD, from The Ohio State University, provides insight into the newly available treatments for chronic lymphocytic leukemia (CLL) and how care for patients with CLL has changed over time.
In this interview, Kerry Rogers,...
03/07/2024
Journal of Clinical Pathways
John Burke, MD, video thumbnail.
Videos
Chronic Lymphocytic Leukemia Pathways in Practice at Rocky Mountain Cancer Centers
02/05/2024

Featuring John Burke, MD

Featuring John Burke, MD
John Burke, MD, discusses the current treatment landscape for chronic lymphocytic leukemia and how his center ensures a comprehensive approach to patient care.
John Burke, MD, discusses the current treatment landscape for chronic lymphocytic leukemia and how his center ensures a comprehensive approach to patient care.
John Burke, MD, discusses the...
02/05/2024
Journal of Clinical Pathways
Ian Flinn video thumbnail.
Recent Developments and Emerging Therapies in Chronic Lymphocytic Leukemia
01/10/2024

Featuring Ian Flinn, MD

Featuring Ian Flinn, MD
Ian Flinn, MD, talks about recent developments in chronic lymphocytic leukemia treatment, emerging therapies that show promise, and how Tennessee Oncology’s new research center will improve access to clinical trials for more patients.
Ian Flinn, MD, talks about recent developments in chronic lymphocytic leukemia treatment, emerging therapies that show promise, and how Tennessee Oncology’s new research center will improve access to clinical trials for more patients.
Ian Flinn, MD, talks about...
01/10/2024
Journal of Clinical Pathways
Video preview thumbnail.
Videos
The Impact of Racial and Socioeconomic Disparities in Patients With Chronic Lymphocytic Leukemia
01/02/2024

Featuring Ira Zackon, MD

Featuring Ira Zackon, MD
Ira Zackon, MD, New York Oncology Hematology, speaks with the Journal of Clinical Pathways about the abstract he presented at the 2023 ASH Annual Meeting & Exposition titled “Racial and Socioeconomic Disparities Among Patients with Chronic...
Ira Zackon, MD, New York Oncology Hematology, speaks with the Journal of Clinical Pathways about the abstract he presented at the 2023 ASH Annual Meeting & Exposition titled “Racial and Socioeconomic Disparities Among Patients with Chronic...
Ira Zackon, MD, New York...
01/02/2024
Journal of Clinical Pathways
Conference Coverage
Trends in the Use of Bruton Tyrosine Kinase Inhibitors and B-cell 2 Inhibitors for Treating CLL in Community Oncology Settings
11/29/2023

Edited by Grace Taylor

Edited by Grace Taylor
Jing-Zhou Hou, MD, and colleagues analyzed the implementation and influences of BTKis and BCL2is for treating patients with CLL among community oncologists since 2020.
Jing-Zhou Hou, MD, and colleagues analyzed the implementation and influences of BTKis and BCL2is for treating patients with CLL among community oncologists since 2020.
Jing-Zhou Hou, MD, and...
11/29/2023
Journal of Clinical Pathways
News
Racial Differences in Ibrutinib Treatment Outcomes in Patients With CLL: A Real-World Analysis
11/28/2023

Edited by Emry Lloyd

Edited by Emry Lloyd
Study on real-world data on patients with chronic lymphocytic leukemia investigated the outcomes for both Black and White patients.
Study on real-world data on patients with chronic lymphocytic leukemia investigated the outcomes for both Black and White patients.
Study on real-world data on...
11/28/2023
Journal of Clinical Pathways

Advertisement

Advertisement

JCP March/April 2024

Current Issue

April 2024
Volume 10
Issue 2
Current Issue
Issue Archive

Advertisement

Advertisement

Special Reports

JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Winston Wong, PharmD
Gordon Kuntz
Robin T Zon, MD, FACP, FASCO
2021 Care Pathways Working Group
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

Advertisement

Subscribe

Journal of Clinical Pathways Newsletter

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use

Advertisement

Advertisement